HEADER CALCIUM/PHOSPHOLIPID-BINDING 10-DEC-97 1HAK TITLE CRYSTAL STRUCTURE OF RECOMBINANT HUMAN PLACENTAL ANNEXIN V COMPLEXED TITLE 2 WITH K-201 AS A CALCIUM CHANNEL ACTIVITY INHIBITOR COMPND MOL_ID: 1; COMPND 2 MOLECULE: ANNEXIN V; COMPND 3 CHAIN: B, A; COMPND 4 FRAGMENT: ANNEXIN FOLD; COMPND 5 SYNONYM: LIPOCORTIN V, ENDONEXIN II, PLACENTA ANTICOAGULANT PROTEIN- COMPND 6 I, 35KDA CALELECTRIN, INHIBITOR OF BLOOD COAGULATION; COMPND 7 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 CELL_LINE: 293; SOURCE 6 ORGAN: PLACENTA; SOURCE 7 CELLULAR_LOCATION: CYTOPLASM; SOURCE 8 GENE: CDNA; SOURCE 9 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 10 EXPRESSION_SYSTEM_TAXID: 562; SOURCE 11 EXPRESSION_SYSTEM_STRAIN: JM105; SOURCE 12 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 13 EXPRESSION_SYSTEM_VECTOR: PKK233-2 KEYWDS ANNEXIN V, LIPOCORTIN V, ENDONEXIN II, PLACENTA ANTICOAGULANT KEYWDS 2 PROTEIN-I, 35KDA CALELECTRIN, INHIBITOR OF BLOOD COAGULATION, KEYWDS 3 CALCIUM/PHOSPHOLIPID-BINDING, CALCIUM-PHOSPHOLIPID-BINDING COMPLEX EXPDTA X-RAY DIFFRACTION AUTHOR H.AGO,E.INAGAKI,M.MIYANO REVDAT 3 09-AUG-23 1HAK 1 REMARK REVDAT 2 24-FEB-09 1HAK 1 VERSN REVDAT 1 16-FEB-99 1HAK 0 JRNL AUTH N.KANEKO,H.AGO,R.MATSUDA,E.INAGAKI,M.MIYANO JRNL TITL CRYSTAL STRUCTURE OF ANNEXIN V WITH ITS LIGAND K-201 AS A JRNL TITL 2 CALCIUM CHANNEL ACTIVITY INHIBITOR. JRNL REF J.MOL.BIOL. V. 274 16 1997 JRNL REFN ISSN 0022-2836 JRNL PMID 9398511 JRNL DOI 10.1006/JMBI.1997.1375 REMARK 1 REMARK 1 REFERENCE 1 REMARK 1 AUTH N.KANEKO REMARK 1 TITL NEW 1,4-BEZOTHIAZEPIN DERIVATIVE, K201, DEMONSTRATES REMARK 1 TITL 2 CARDIOPROTECTIVE EFFECTS AGAINST SUDDEN CARDIAC CELL DEATH REMARK 1 TITL 3 AND INTRACELLULAR CALCIUM BLOCKING ACTION REMARK 1 REF DRUG DEV.RES. V. 33 429 1994 REMARK 1 REFN ISSN 0272-4391 REMARK 1 REFERENCE 2 REMARK 1 AUTH R.HUBER,R.BERENDES,A.BURGER,M.SCHNEIDER,A.KARSHIKOV, REMARK 1 AUTH 2 H.LUECKE,J.ROMISCH,E.PAQUES REMARK 1 TITL CRYSTAL AND MOLECULAR STRUCTURE OF HUMAN ANNEXIN V AFTER REMARK 1 TITL 2 REFINEMENT. IMPLICATIONS FOR STRUCTURE, MEMBRANE BINDING AND REMARK 1 TITL 3 ION CHANNEL FORMATION OF THE ANNEXIN FAMILY OF PROTEINS REMARK 1 REF J.MOL.BIOL. V. 223 683 1992 REMARK 1 REFN ISSN 0022-2836 REMARK 1 REFERENCE 3 REMARK 1 AUTH A.IWASAKI,M.SUDA,H.NAKAO,T.NAGOYA,Y.SAINO,K.ARAI, REMARK 1 AUTH 2 T.MIZOGUCHI,F.SATO,H.YOSHIZAKI,M.HIRATA,T.MIYATA,Y.SHIDARA, REMARK 1 AUTH 3 M.MURATA,M.MAKI REMARK 1 TITL STRUCTURE AND EXPRESSION OF CDNA FOR AN INHIBITOR OF BLOOD REMARK 1 TITL 2 COAGULATION ISOLATED FROM HUMAN PLACENTA: A NEW REMARK 1 TITL 3 LIPOCORTIN-LIKE PROTEIN REMARK 1 REF J.BIOCHEM.(TOKYO) V. 102 1261 1987 REMARK 1 REFN ISSN 0021-924X REMARK 2 REMARK 2 RESOLUTION. 3.00 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : X-PLOR 3.1 REMARK 3 AUTHORS : BRUNGER REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 3.00 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 20.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : 2.000 REMARK 3 DATA CUTOFF HIGH (ABS(F)) : 100000.000 REMARK 3 DATA CUTOFF LOW (ABS(F)) : 0.1000 REMARK 3 COMPLETENESS (WORKING+TEST) (%) : 97.4 REMARK 3 NUMBER OF REFLECTIONS : 14609 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING SET) : 0.206 REMARK 3 FREE R VALUE : 0.331 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.000 REMARK 3 FREE R VALUE TEST SET COUNT : 701 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : 0.013 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 8 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 3.00 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 3.14 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 93.40 REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 1626 REMARK 3 BIN R VALUE (WORKING SET) : 0.2730 REMARK 3 BIN FREE R VALUE : 0.3480 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : 5.00 REMARK 3 BIN FREE R VALUE TEST SET COUNT : 78 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : 0.006 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 5026 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 60 REMARK 3 SOLVENT ATOMS : 109 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : 12.60 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : NULL REMARK 3 B22 (A**2) : NULL REMARK 3 B33 (A**2) : NULL REMARK 3 B12 (A**2) : NULL REMARK 3 B13 (A**2) : NULL REMARK 3 B23 (A**2) : NULL REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : NULL REMARK 3 ESD FROM SIGMAA (A) : NULL REMARK 3 LOW RESOLUTION CUTOFF (A) : NULL REMARK 3 REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : NULL REMARK 3 ESD FROM C-V SIGMAA (A) : NULL REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.023 REMARK 3 BOND ANGLES (DEGREES) : 3.450 REMARK 3 DIHEDRAL ANGLES (DEGREES) : 25.50 REMARK 3 IMPROPER ANGLES (DEGREES) : 2.428 REMARK 3 REMARK 3 ISOTROPIC THERMAL MODEL : NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 REMARK 3 NCS MODEL : NULL REMARK 3 REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL REMARK 3 REMARK 3 PARAMETER FILE 1 : PARHCSDX.PRO REMARK 3 PARAMETER FILE 2 : NULL REMARK 3 PARAMETER FILE 3 : NULL REMARK 3 TOPOLOGY FILE 1 : AMINO.RTF REMARK 3 TOPOLOGY FILE 2 : NULL REMARK 3 TOPOLOGY FILE 3 : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: THE PSF FILE FOR X-PLOR REFINEMENT WAS REMARK 3 CREATED USING QUANTA/CHARMM. REMARK 4 REMARK 4 1HAK COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY BNL. REMARK 100 THE DEPOSITION ID IS D_1000173747. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 14-SEP-95 REMARK 200 TEMPERATURE (KELVIN) : 298 REMARK 200 PH : 7.5 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : N REMARK 200 RADIATION SOURCE : ROTATING ANODE REMARK 200 BEAMLINE : NULL REMARK 200 X-RAY GENERATOR MODEL : RIGAKU RUH3R REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.5418 REMARK 200 MONOCHROMATOR : NI FILTER REMARK 200 OPTICS : ASYMMETRIC DOUBLE MIRROR REMARK 200 REMARK 200 DETECTOR TYPE : IMAGE PLATE REMARK 200 DETECTOR MANUFACTURER : RIGAKU RAXIS IIC REMARK 200 INTENSITY-INTEGRATION SOFTWARE : DENZO REMARK 200 DATA SCALING SOFTWARE : SCALEPACK REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 104199 REMARK 200 RESOLUTION RANGE HIGH (A) : 3.000 REMARK 200 RESOLUTION RANGE LOW (A) : 40.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 1.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 98.3 REMARK 200 DATA REDUNDANCY : 4.200 REMARK 200 R MERGE (I) : 0.06800 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 17.6000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : NULL REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : NULL REMARK 200 COMPLETENESS FOR SHELL (%) : NULL REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : NULL REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: NULL REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: AMORE REMARK 200 STARTING MODEL: 1AK0 REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 52.00 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.60 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: PH 7.5 REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 63 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -Y,X-Y,Z REMARK 290 3555 -X+Y,-X,Z REMARK 290 4555 -X,-Y,Z+1/2 REMARK 290 5555 Y,-X+Y,Z+1/2 REMARK 290 6555 X-Y,X,Z+1/2 REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -0.500000 -0.866025 0.000000 0.00000 REMARK 290 SMTRY2 2 0.866025 -0.500000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 3 -0.500000 0.866025 0.000000 0.00000 REMARK 290 SMTRY2 3 -0.866025 -0.500000 0.000000 0.00000 REMARK 290 SMTRY3 3 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 4 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 4 0.000000 0.000000 1.000000 65.25000 REMARK 290 SMTRY1 5 0.500000 0.866025 0.000000 0.00000 REMARK 290 SMTRY2 5 -0.866025 0.500000 0.000000 0.00000 REMARK 290 SMTRY3 5 0.000000 0.000000 1.000000 65.25000 REMARK 290 SMTRY1 6 0.500000 -0.866025 0.000000 0.00000 REMARK 290 SMTRY2 6 0.866025 0.500000 0.000000 0.00000 REMARK 290 SMTRY3 6 0.000000 0.000000 1.000000 65.25000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: B, A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 MET B 1 REMARK 465 ALA B 2 REMARK 465 MET A 1 REMARK 465 ALA A 2 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND LENGTHS REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,2(A3,1X,A1,I4,A1,1X,A4,3X),1X,F6.3) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 RES CSSEQI ATM2 DEVIATION REMARK 500 HIS B 267 CG HIS B 267 CD2 0.057 REMARK 500 ASP A 320 C ASP A 320 OXT 0.118 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND ANGLES REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3 REMARK 500 ASN B 106 CA - CB - CG ANGL. DEV. = -13.3 DEGREES REMARK 500 TYR B 133 CB - CG - CD1 ANGL. DEV. = -4.5 DEGREES REMARK 500 ARG B 227 CA - CB - CG ANGL. DEV. = 13.7 DEGREES REMARK 500 ARG A 50 NE - CZ - NH2 ANGL. DEV. = -3.1 DEGREES REMARK 500 TYR A 91 CB - CG - CD2 ANGL. DEV. = -3.9 DEGREES REMARK 500 TYR A 308 CB - CG - CD2 ANGL. DEV. = -4.3 DEGREES REMARK 500 ASP A 320 N - CA - C ANGL. DEV. = 16.8 DEGREES REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 GLU B 17 -57.67 -23.46 REMARK 500 LEU B 31 174.54 -56.37 REMARK 500 LEU B 39 -71.35 -39.04 REMARK 500 ALA B 159 71.73 46.91 REMARK 500 ASN B 160 46.09 -145.82 REMARK 500 ASP B 168 73.20 -23.34 REMARK 500 LEU B 185 32.49 -89.71 REMARK 500 TRP B 187 38.17 30.60 REMARK 500 GLU B 192 -47.85 -5.39 REMARK 500 GLU B 222 -36.37 -37.86 REMARK 500 ASN B 232 -72.94 19.05 REMARK 500 SER B 246 116.49 -177.11 REMARK 500 THR B 264 173.01 76.56 REMARK 500 ALA B 293 15.28 50.04 REMARK 500 GLU B 318 -22.50 179.30 REMARK 500 LEU A 31 70.45 37.85 REMARK 500 ILE A 38 -70.82 -49.87 REMARK 500 ASN A 47 -67.46 -24.58 REMARK 500 ASP A 64 94.82 -67.98 REMARK 500 MET A 85 36.39 -87.00 REMARK 500 LEU A 100 -70.50 -104.73 REMARK 500 ALA A 159 9.09 46.17 REMARK 500 ALA A 165 -150.24 -154.61 REMARK 500 LEU A 185 33.13 -92.26 REMARK 500 LYS A 186 22.94 45.46 REMARK 500 ASP A 190 -51.49 60.95 REMARK 500 GLU A 191 -75.84 49.58 REMARK 500 ASP A 226 81.08 -66.56 REMARK 500 ARG A 227 -44.21 -28.20 REMARK 500 ASN A 232 -71.50 6.10 REMARK 500 SER A 246 116.96 -175.87 REMARK 500 ILE A 279 -72.77 -122.83 REMARK 500 GLU A 318 5.81 -64.85 REMARK 500 ASP A 319 -155.71 -139.81 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: NON-CIS, NON-TRANS REMARK 500 REMARK 500 THE FOLLOWING PEPTIDE BONDS DEVIATE SIGNIFICANTLY FROM BOTH REMARK 500 CIS AND TRANS CONFORMATION. CIS BONDS, IF ANY, ARE LISTED REMARK 500 ON CISPEP RECORDS. TRANS IS DEFINED AS 180 +/- 30 AND REMARK 500 CIS IS DEFINED AS 0 +/- 30 DEGREES. REMARK 500 MODEL OMEGA REMARK 500 THR B 105 ASN B 106 -129.00 REMARK 500 GLU B 191 GLU B 192 144.70 REMARK 500 SER B 204 HIS B 205 148.03 REMARK 500 ALA B 293 THR B 294 143.61 REMARK 500 GLY A 30 LEU A 31 65.35 REMARK 500 ASP A 319 ASP A 320 141.88 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: PLANAR GROUPS REMARK 500 REMARK 500 PLANAR GROUPS IN THE FOLLOWING RESIDUES HAVE A TOTAL REMARK 500 RMS DISTANCE OF ALL ATOMS FROM THE BEST-FIT PLANE REMARK 500 BY MORE THAN AN EXPECTED VALUE OF 6*RMSD, WITH AN REMARK 500 RMSD 0.02 ANGSTROMS, OR AT LEAST ONE ATOM HAS REMARK 500 AN RMSD GREATER THAN THIS VALUE REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 M RES CSSEQI RMS TYPE REMARK 500 ARG B 50 0.08 SIDE CHAIN REMARK 500 TYR B 148 0.07 SIDE CHAIN REMARK 500 ARG B 161 0.08 SIDE CHAIN REMARK 500 PHE B 198 0.08 SIDE CHAIN REMARK 500 ARG B 276 0.10 SIDE CHAIN REMARK 500 TYR B 297 0.08 SIDE CHAIN REMARK 500 ARG A 45 0.11 SIDE CHAIN REMARK 500 TYR A 94 0.10 SIDE CHAIN REMARK 500 ARG A 151 0.15 SIDE CHAIN REMARK 500 ARG A 245 0.08 SIDE CHAIN REMARK 500 TYR A 256 0.11 SIDE CHAIN REMARK 500 TYR A 257 0.10 SIDE CHAIN REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE K21 B 901 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE K21 A 901 DBREF 1HAK B 2 320 UNP P08758 ANXA5_HUMAN 1 319 DBREF 1HAK A 2 320 UNP P08758 ANXA5_HUMAN 1 319 SEQRES 1 B 320 MET ALA GLN VAL LEU ARG GLY THR VAL THR ASP PHE PRO SEQRES 2 B 320 GLY PHE ASP GLU ARG ALA ASP ALA GLU THR LEU ARG LYS SEQRES 3 B 320 ALA MET LYS GLY LEU GLY THR ASP GLU GLU SER ILE LEU SEQRES 4 B 320 THR LEU LEU THR SER ARG SER ASN ALA GLN ARG GLN GLU SEQRES 5 B 320 ILE SER ALA ALA PHE LYS THR LEU PHE GLY ARG ASP LEU SEQRES 6 B 320 LEU ASP ASP LEU LYS SER GLU LEU THR GLY LYS PHE GLU SEQRES 7 B 320 LYS LEU ILE VAL ALA LEU MET LYS PRO SER ARG LEU TYR SEQRES 8 B 320 ASP ALA TYR GLU LEU LYS HIS ALA LEU LYS GLY ALA GLY SEQRES 9 B 320 THR ASN GLU LYS VAL LEU THR GLU ILE ILE ALA SER ARG SEQRES 10 B 320 THR PRO GLU GLU LEU ARG ALA ILE LYS GLN VAL TYR GLU SEQRES 11 B 320 GLU GLU TYR GLY SER SER LEU GLU ASP ASP VAL VAL GLY SEQRES 12 B 320 ASP THR SER GLY TYR TYR GLN ARG MET LEU VAL VAL LEU SEQRES 13 B 320 LEU GLN ALA ASN ARG ASP PRO ASP ALA GLY ILE ASP GLU SEQRES 14 B 320 ALA GLN VAL GLU GLN ASP ALA GLN ALA LEU PHE GLN ALA SEQRES 15 B 320 GLY GLU LEU LYS TRP GLY THR ASP GLU GLU LYS PHE ILE SEQRES 16 B 320 THR ILE PHE GLY THR ARG SER VAL SER HIS LEU ARG LYS SEQRES 17 B 320 VAL PHE ASP LYS TYR MET THR ILE SER GLY PHE GLN ILE SEQRES 18 B 320 GLU GLU THR ILE ASP ARG GLU THR SER GLY ASN LEU GLU SEQRES 19 B 320 GLN LEU LEU LEU ALA VAL VAL LYS SER ILE ARG SER ILE SEQRES 20 B 320 PRO ALA TYR LEU ALA GLU THR LEU TYR TYR ALA MET LYS SEQRES 21 B 320 GLY ALA GLY THR ASP ASP HIS THR LEU ILE ARG VAL MET SEQRES 22 B 320 VAL SER ARG SER GLU ILE ASP LEU PHE ASN ILE ARG LYS SEQRES 23 B 320 GLU PHE ARG LYS ASN PHE ALA THR SER LEU TYR SER MET SEQRES 24 B 320 ILE LYS GLY ASP THR SER GLY ASP TYR LYS LYS ALA LEU SEQRES 25 B 320 LEU LEU LEU CYS GLY GLU ASP ASP SEQRES 1 A 320 MET ALA GLN VAL LEU ARG GLY THR VAL THR ASP PHE PRO SEQRES 2 A 320 GLY PHE ASP GLU ARG ALA ASP ALA GLU THR LEU ARG LYS SEQRES 3 A 320 ALA MET LYS GLY LEU GLY THR ASP GLU GLU SER ILE LEU SEQRES 4 A 320 THR LEU LEU THR SER ARG SER ASN ALA GLN ARG GLN GLU SEQRES 5 A 320 ILE SER ALA ALA PHE LYS THR LEU PHE GLY ARG ASP LEU SEQRES 6 A 320 LEU ASP ASP LEU LYS SER GLU LEU THR GLY LYS PHE GLU SEQRES 7 A 320 LYS LEU ILE VAL ALA LEU MET LYS PRO SER ARG LEU TYR SEQRES 8 A 320 ASP ALA TYR GLU LEU LYS HIS ALA LEU LYS GLY ALA GLY SEQRES 9 A 320 THR ASN GLU LYS VAL LEU THR GLU ILE ILE ALA SER ARG SEQRES 10 A 320 THR PRO GLU GLU LEU ARG ALA ILE LYS GLN VAL TYR GLU SEQRES 11 A 320 GLU GLU TYR GLY SER SER LEU GLU ASP ASP VAL VAL GLY SEQRES 12 A 320 ASP THR SER GLY TYR TYR GLN ARG MET LEU VAL VAL LEU SEQRES 13 A 320 LEU GLN ALA ASN ARG ASP PRO ASP ALA GLY ILE ASP GLU SEQRES 14 A 320 ALA GLN VAL GLU GLN ASP ALA GLN ALA LEU PHE GLN ALA SEQRES 15 A 320 GLY GLU LEU LYS TRP GLY THR ASP GLU GLU LYS PHE ILE SEQRES 16 A 320 THR ILE PHE GLY THR ARG SER VAL SER HIS LEU ARG LYS SEQRES 17 A 320 VAL PHE ASP LYS TYR MET THR ILE SER GLY PHE GLN ILE SEQRES 18 A 320 GLU GLU THR ILE ASP ARG GLU THR SER GLY ASN LEU GLU SEQRES 19 A 320 GLN LEU LEU LEU ALA VAL VAL LYS SER ILE ARG SER ILE SEQRES 20 A 320 PRO ALA TYR LEU ALA GLU THR LEU TYR TYR ALA MET LYS SEQRES 21 A 320 GLY ALA GLY THR ASP ASP HIS THR LEU ILE ARG VAL MET SEQRES 22 A 320 VAL SER ARG SER GLU ILE ASP LEU PHE ASN ILE ARG LYS SEQRES 23 A 320 GLU PHE ARG LYS ASN PHE ALA THR SER LEU TYR SER MET SEQRES 24 A 320 ILE LYS GLY ASP THR SER GLY ASP TYR LYS LYS ALA LEU SEQRES 25 A 320 LEU LEU LEU CYS GLY GLU ASP ASP HET K21 B 901 30 HET K21 A 901 30 HETNAM K21 4-[3-{1-(4-BENZYL)PIPERODINYL}PROPIONYL]-7-METHOXY-2,3, HETNAM 2 K21 4,5-TERTRAHYDRO-1,4-BENZOTHIAZEPINE HETSYN K21 K201 FORMUL 3 K21 2(C25 H32 N2 O2 S) FORMUL 5 HOH *109(H2 O) HELIX 1 1 GLU B 17 ALA B 27 1 11 HELIX 2 2 GLU B 35 SER B 44 1 10 HELIX 3 3 ASN B 47 PHE B 61 1 15 HELIX 4 4 LEU B 65 GLU B 72 1 8 HELIX 5 5 GLY B 75 MET B 85 1 11 HELIX 6 6 SER B 88 LYS B 101 1 14 HELIX 7 7 GLU B 107 SER B 116 1 10 HELIX 8 8 PRO B 119 TYR B 133 1 15 HELIX 9 9 LEU B 137 ASP B 144 1 8 HELIX 10 10 GLY B 147 GLN B 158 1 12 HELIX 11 11 GLU B 169 GLU B 184 1 16 HELIX 12 12 GLU B 191 GLY B 199 1 9 HELIX 13 13 VAL B 203 SER B 217 1 15 HELIX 14 14 ILE B 221 THR B 224 5 4 HELIX 15 15 ASN B 232 ARG B 245 1 14 HELIX 16 16 ILE B 247 MET B 259 1 13 HELIX 17 17 ASP B 266 ARG B 276 1 11 HELIX 18 18 LEU B 281 PHE B 292 1 12 HELIX 19 19 LEU B 296 ASP B 303 1 8 HELIX 20 20 GLY B 306 CYS B 316 1 11 HELIX 21 21 GLU A 17 MET A 28 1 12 HELIX 22 22 GLU A 35 SER A 44 1 10 HELIX 23 23 ASN A 47 PHE A 61 1 15 HELIX 24 24 LEU A 65 SER A 71 1 7 HELIX 25 25 GLY A 75 LEU A 84 1 10 HELIX 26 26 SER A 88 LEU A 100 1 13 HELIX 27 27 GLU A 107 SER A 116 1 10 HELIX 28 28 PRO A 119 GLU A 132 1 14 HELIX 29 29 LEU A 137 ASP A 144 1 8 HELIX 30 30 GLY A 147 GLN A 158 1 12 HELIX 31 31 GLU A 169 GLU A 184 1 16 HELIX 32 32 GLU A 191 THR A 200 5 10 HELIX 33 33 VAL A 203 SER A 217 1 15 HELIX 34 34 ILE A 221 THR A 224 1 4 HELIX 35 35 ASN A 232 ARG A 245 1 14 HELIX 36 36 ILE A 247 MET A 259 1 13 HELIX 37 37 ASP A 266 GLU A 278 1 13 HELIX 38 38 LEU A 281 PHE A 292 1 12 HELIX 39 39 LEU A 296 ASP A 303 1 8 HELIX 40 40 GLY A 306 CYS A 316 1 11 SITE 1 AC1 12 LEU B 5 THR B 118 PRO B 119 GLU B 121 SITE 2 AC1 12 ARG B 161 VAL B 203 ARG B 207 SER B 243 SITE 3 AC1 12 ILE B 244 ILE B 247 ARG B 276 ILE B 279 SITE 1 AC2 8 LEU A 5 THR A 118 PRO A 119 ARG A 161 SITE 2 AC2 8 VAL A 203 ARG A 207 SER A 243 ILE A 244 CRYST1 99.300 99.300 130.500 90.00 90.00 120.00 P 63 12 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.010070 0.005814 0.000000 0.00000 SCALE2 0.000000 0.011628 0.000000 0.00000 SCALE3 0.000000 0.000000 0.007663 0.00000